Shares of Precision BioSciences (DTIL) rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast Track designation to PBGENE-HBV. This is DTIL’s lead, fully owned in vivo gene editing program aimed at curing chronic hepatitis B by eliminating cccDNA — the primary source of replicating hepatitis B virus (HBV) — and inactivating integrated HBV DNA in liver cells (hepatocytes).The FDA’s Fast Track designation is intended to speed up the development and review of drugs that treat s ...